- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Olicon slashes sales force for OEM focus
PACS and teleradiology vendor Olicon Imaging Systems has apparently cut its direct sales force to focus on its OEM relationship with healthcare information systems firm Shared Medical Systems. Olicon executives declined to return calls seeking comment,
PACS and teleradiology vendor Olicon Imaging Systems has apparently cut its direct sales force to focus on its OEM relationship with healthcare information systems firm Shared Medical Systems. Olicon executives declined to return calls seeking comment, but a source close to the situation confirmed the reduction in Olicons direct sales force and change in the Aliso Viejo, CA-based companys direction.
The two firms signed an agreement in August that would allow SMS to offer Olicons diagnostic workstations and PACSView teleradiology offerings to its customers. That deal built on a relationship in evidence at the 1997 Radiological Society of North America meeting, where Olicon workstations were displayed in the booth of Malvern, PA-based SMS (SCAN Special Report 12/97). Olicon will be keeping its booth at this years RSNA meeting, according to a RSNA source.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
